abstract |
The invention relates the use of a cathepsin K inhibitor (CTKI) or CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof in the manufacture of a medicament for treating a disease in which SDF-1 activity and/or concentration is involved with the development and/or course of the disease. |